ODI Pharma AB (ODI.ST)

SEK 2.76

(-8.0%)

Operating Income Summary of ODI Pharma AB

  • ODI Pharma AB's latest annual operating income in 2023 was -1.34 Million SEK , up 80.31% from previous year.
  • ODI Pharma AB's latest quarterly operating income in 2023 FY was -1.34 Million SEK , up 80.31% from previous quarter.
  • ODI Pharma AB reported an annual operating income of -6.81 Million SEK in 2022, up 5.77% from previous year.
  • ODI Pharma AB reported an annual operating income of -7.23 Million SEK in 2021, down -84.2% from previous year.
  • ODI Pharma AB reported a quarterly operating income of 1.45 Million SEK for 2023 Q3, up 178.42% from previous quarter.
  • ODI Pharma AB reported a quarterly operating income of -1.17 Million SEK for 2023 Q1, up 55.22% from previous quarter.

Annual Operating Income Chart of ODI Pharma AB (2023 - 2018)

Historical Annual Operating Income of ODI Pharma AB (2023 - 2018)

Year Operating Income Operating Income Growth
2023 -1.34 Million SEK 80.31%
2022 -6.81 Million SEK 5.77%
2021 -7.23 Million SEK -84.2%
2020 -3.92 Million SEK 16.78%
2019 -4.71 Million SEK -36.3%
2018 -3.46 Million SEK 0.0%

Peer Operating Income Comparison of ODI Pharma AB

Name Operating Income Operating Income Difference
AcuCort AB -13.24 Million SEK 89.874%
AlzeCure Pharma AB (publ) -38.26 Million SEK 96.494%
BioGaia AB (publ) 440.9 Million SEK 100.304%
Enzymatica AB (publ) -48.06 Million SEK 97.209%
Enorama Pharma AB (publ) -41.83 Million SEK 96.793%
Gabather AB (publ) -9.47 Million SEK 85.839%
Klaria Pharma Holding AB (publ.) -14.68 Million SEK 90.861%
Moberg Pharma AB (publ) -27.46 Million SEK 95.115%
Nanexa AB (publ) -76.62 Million SEK 98.249%
Newbury Pharmaceuticals AB (publ) -14.07 Million SEK 90.47%
Orexo AB (publ) -109.5 Million SEK 98.775%
Probi AB (publ) 11.32 Million SEK 111.852%
Swedencare AB (publ) 173.2 Million SEK 100.775%
Swedish Orphan Biovitrum AB (publ) 4.65 Billion SEK 100.029%
Toleranzia AB -7.89 Million SEK 82.998%
Vivesto AB -356.71 Million SEK 99.624%